Health Care [ 3/12 ] | Biotechnology [ 14/73 ]
NASDAQ | Common Stock
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide.
It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050.
In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.
It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 4, 25 | -3.31 Decreased by -90.23% | -3.25 Decreased by -1.85% |
| May 12, 25 | -3.29 Decreased by -15.85% | -2.07 Decreased by -58.94% |
| Mar 3, 25 | -2.94 Increased by +1.01% | -2.82 Decreased by -4.29% |
| Nov 5, 24 | -2.75 Decreased by -1.43 K% | -1.99 Decreased by -38.19% |
| Aug 13, 24 | -1.74 Decreased by -255.10% | -2.31 Increased by +24.68% |
| May 13, 24 | -2.84 Decreased by -300.00% | -2.08 Decreased by -36.54% |
| Mar 5, 24 | -2.97 Decreased by -241.38% | -3.18 Increased by +6.60% |
| Nov 7, 23 | -0.18 Increased by +81.25% | -0.35 Increased by +48.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by -100.00% | -71.13 M Decreased by -117.67% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -69.30 M Decreased by -75.20% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 7.46 M Increased by +1.35 K% | -58.68 M Decreased by -118.32% | Decreased by -786.27% Increased by +84.93% |
| Sep 30, 24 | 302.00 K Decreased by -35.47% | -51.91 M Decreased by -110.74% | Decreased by -17.19 K% Decreased by -226.58% |
| Jun 30, 24 | 357.00 K Decreased by -54.29% | -32.68 M Increased by +4.77% | Decreased by -9.15 K% Decreased by -108.34% |
| Mar 31, 24 | 431.00 K Decreased by -36.90% | -39.55 M Decreased by -7.43% | Decreased by -9.18 K% Decreased by -70.24% |
| Dec 31, 23 | 515.00 K Increased by +N/A% | -26.88 M Increased by +34.27% | Decreased by -5.22 K% Decreased by N/A% |
| Sep 30, 23 | 468.00 K Increased by +N/A% | -24.63 M Increased by +43.50% | Decreased by -5.26 K% Decreased by N/A% |